Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 2/20 | 0.50 |
| ▸ | JAK2 | O60674 | 8/20 | 0.49 |
| ▸ | BRD4 | O60885 | 8/20 | 0.48 |
| ▸ | FLT3 | P36888 | 2/20 | 0.47 |
| ▸ | BTK | Q06187 | 1/20 | 0.47 |
| ▸ | CDK4 | P11802 | 2/20 | 0.46 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.46 |
| ▸ | CSF1R | P07333 | 1/20 | 0.46 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.46 |
| ▸ | JAK1 | P23458 | 4/20 | 0.46 |
| ▸ | JAK3 | P52333 | 4/20 | 0.46 |
| ▸ | BRDT | Q58F21 | 3/20 | 0.46 |
| ▸ | BRD2 | P25440 | 2/20 | 0.46 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.46 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.45 |
| ▸ | TYK2 | P29597 | 1/20 | 0.45 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.44 |
| ▸ | CCND1 | P24385 | 1/20 | 0.44 |
| ▸ | CCND3 | P30281 | 1/20 | 0.44 |
| ▸ | CDK9 | P50750 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1115415 | 0.87 | TNK2 (0.52) | BRD4CDK4CDK6JAK3TNK2 | |
| SCHEMBL1115315 | 0.80 | TNK2 (0.55) | FLT3CDK4CDK6JAK3TNK2 | |
| SCHEMBL1115422 | 0.76 | CDK4 (0.49) | CDK4CDK6TNK2CCND1CCND3 | |
| SCHEMBL29575740 | 0.74 | AXL (0.62) | AXLJAK2BRD4FLT3BTK | |
| SCHEMBL1633898 | 0.73 | BRD4 (0.56) | AXLJAK2BRD4FLT3CDK4 | |
| SCHEMBL1115453 | 0.72 | LRRK2 (0.53) | AXLJAK2CDK4CDK6JAK1 | |
| SCHEMBL1633250 | 0.71 | AXL (0.52) | AXLJAK2BRD4BTKCDK4 | |
| SCHEMBL30017942 | 0.69 | BTK (0.57) | AXLJAK2BRD4FLT3BTK | |
| SCHEMBL1115436 | 0.69 | WEE1 (0.47) | JAK2BRD4CDK4CDK6JAK1 | |
| SCHEMBL1115244 | 0.68 | CDK4 (0.49) | CDK4CDK6CCND1CCND3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389533-B2 | Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors | AMGEN INC. (US) | 2013-03-05 | — | — | US | claimed |
| EP-2278973-B1 | GEM-DISUBSTITUTED AND SPIROCYCLIC AMINO PYRIDINES/PYRIMIDINES AS CELL CYCLE INHIBITORS | AMGEN INC (US) | 2011-11-02 | — | — | EP | claimed |
| US-20110097305-A1 | Gem-Disubstituted and Spirocyclic Amino Pyridines/Pyrimidines as Cell Cycle Inhibitors | AMGEN INC. (US) | 2011-04-28 | — | — | US | claimed |
| EP-2278973-A1 | GEM-DISUBSTITUTED AND SPIROCYCLIC AMINO PYRIDINES/PYRIMIDINES AS CELL CYCLE INHIBITORS | Amgen Inc. (US) | 2011-02-02 | — | — | EP | claimed |
| WO-2009126584-A1 | GEM-DISUBSTITUTED AND SPIROCYCLIC AMINO PYRIDINES/PYRIMIDINES AS CELL CYCLE INHIBITORS | AMGEN INC. (US) | 2009-10-15 | — | — | WO | claimed |
| US-8389533-B2 | Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors | AMGEN INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-8389533-B2 | Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors | AMGEN INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-8389533-B2 | Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors | AMGEN INC. (US) | 2013-03-05 | — | — | US | disclosed |
| EP-2278973-B1 | GEM-DISUBSTITUTED AND SPIROCYCLIC AMINO PYRIDINES/PYRIMIDINES AS CELL CYCLE INHIBITORS | AMGEN INC (US) | 2011-11-02 | — | — | EP | disclosed |
| EP-2278973-B1 | GEM-DISUBSTITUTED AND SPIROCYCLIC AMINO PYRIDINES/PYRIMIDINES AS CELL CYCLE INHIBITORS | AMGEN INC (US) | 2011-11-02 | — | — | EP | disclosed |
| US-20110097305-A1 | Gem-Disubstituted and Spirocyclic Amino Pyridines/Pyrimidines as Cell Cycle Inhibitors | AMGEN INC. (US) | 2011-04-28 | — | — | US | disclosed |
| US-20110097305-A1 | Gem-Disubstituted and Spirocyclic Amino Pyridines/Pyrimidines as Cell Cycle Inhibitors | AMGEN INC. (US) | 2011-04-28 | — | — | US | disclosed |
| US-20110097305-A1 | Gem-Disubstituted and Spirocyclic Amino Pyridines/Pyrimidines as Cell Cycle Inhibitors | AMGEN INC. (US) | 2011-04-28 | — | — | US | disclosed |
| EP-2278973-A1 | GEM-DISUBSTITUTED AND SPIROCYCLIC AMINO PYRIDINES/PYRIMIDINES AS CELL CYCLE INHIBITORS | Amgen Inc. (US) | 2011-02-02 | — | — | EP | disclosed |
| WO-2009126584-A1 | GEM-DISUBSTITUTED AND SPIROCYCLIC AMINO PYRIDINES/PYRIMIDINES AS CELL CYCLE INHIBITORS | AMGEN INC. (US) | 2009-10-15 | — | — | WO | disclosed |
| WO-2009126584-A1 | GEM-DISUBSTITUTED AND SPIROCYCLIC AMINO PYRIDINES/PYRIMIDINES AS CELL CYCLE INHIBITORS | AMGEN INC. (US) | 2009-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110097305-A1 | Gem-Disubstituted and Spirocyclic Amino Pyridines/Pyrimidines as Cell Cycle Inhibitors | CDK4, CDK3, CDK6 | AXL 478/4885JAK2 333/4885BRD4 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.